Home > Boards > US Listed > Biotechs > INSMED (INSM)

Been a long time. Was the drug involved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 198
Posts 16,287
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 5:17:35 PM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 8/7/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 7:31:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 7:31:02 AM
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire (US) - 8/6/2020 7:30:00 AM
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020 PR Newswire (US) - 7/27/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 9:38:47 AM
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infect... PR Newswire (US) - 7/24/2020 7:39:00 AM
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infect... PR Newswire (US) - 7/24/2020 7:36:00 AM
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patient... PR Newswire (US) - 7/7/2020 8:00:00 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 7/6/2020 8:00:00 AM
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at AT... PR Newswire (US) - 6/24/2020 4:01:00 PM
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCF... PR Newswire (US) - 6/8/2020 8:00:00 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 6/5/2020 8:00:00 AM
Insmed to Present at Two June Conferences PR Newswire (US) - 5/26/2020 8:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 5/21/2020 4:10:30 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/21/2020 4:08:11 PM
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session PR Newswire (US) - 5/20/2020 9:29:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2020 4:02:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 10:59:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 8:32:02 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 5/7/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/5/2020 5:30:59 PM
Insmed Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 5/5/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/4/2020 4:13:29 PM
north40000 Member Level  Friday, 09/15/17 11:14:07 AM
Re: north40000 post# 6470
Post # of 6484 
Been a long time. Was the drug involved there Iplex and the DNA patent one of Cabiily that evolved from an interference DNA lost in PTO but won in settlement in D.Ct.? That DNA/Roche patent should be about to expire, if it hasn't already expired.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist